summary
Introduced
04/28/2021
04/28/2021
In Committee
09/29/2021
09/29/2021
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or inter- changeable biological product into the market.
AI Summary
This bill, the Preserve Access to Affordable Generics and Biosimilars Act, aims to enhance competition in the pharmaceutical market by prohibiting anticompetitive agreements between manufacturers of brand-name and generic drug products or biosimilar biological products that limit, delay, or prevent competition from generic drugs and biosimilar biological products. The bill establishes a presumption that certain types of agreements between brand-name and generic drug manufacturers or biosimilar biological product manufacturers are anticompetitive and a violation of the Federal Trade Commission Act, unless the parties can demonstrate clear and convincing evidence that the agreement's benefits outweigh its anticompetitive effects. The bill also includes provisions related to notice, certification, and enforcement of these types of agreements.
Committee Categories
Health and Social Services, Justice
Sponsors (8)
Jerry Nadler (D)*,
Ken Buck (R),
Ted Budd (R),
David Cicilline (D),
Sheila Jackson-Lee (D),
Carolyn Maloney (D),
Eleanor Holmes Norton (D),
Burgess Owens (R),
Last Action
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13. (on 09/29/2021)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/house-bill/2891/all-info |
| BillText | https://www.congress.gov/117/bills/hr2891/BILLS-117hr2891ih.pdf |
| Bill | https://www.congress.gov/117/bills/hr2891/BILLS-117hr2891ih.pdf.pdf |
Loading...